OS Therapies: OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmona
OS Therapies (NYSE American: OSTX) said the U.S. FDA granted a Type C Statistical Methods meeting to review 2.5-year overall survival data for OST-HER2 from a Phase 2b trial in fully resected pulmonary metastatic osteosarcoma. Interim 3-year OS data are expected early Sept 2026. FDA comparator, RMAT, and Rolling Review decisions are expected after the mid-Sept 2026 meeting.
How this was made
The 30-second read
Why it matters
The FDA meeting is a procedural but concrete regulatory step that should clarify the comparator arm and statistical approach for interpreting 2.5-year overall survival, potentially accelerating subsequent decisions on RMAT submission, Rolling Review, and priority review voucher pathway.
Market read
Traders can position around the early-September interim 3-year OS data and the mid-September FDA statistical-methods meeting that may determine how efficacy is judged.
What to watch
The release does not provide the magnitude of the 2.5-year OS result, only that it was unchanged from 2-year; market may discount the milestone if interim 3-year OS data disappoints or if FDA rejects the proposed historical-control approach.
Background
OS Therapies is seeking U.S. BLA support for OST-HER2 in pulmonary metastatic osteosarcoma, with RMAT and Rolling Review tied to efficacy interpretation and statistical methods.
Ticker impact
FDA granted OS Therapies a Type C Statistical Methods meeting to review 2.5-year overall survival data for OST-HER2 in mid-September 2026.
Likely positive bias into the interim 3-year OS readout and the mid-September statistical-methods meeting, with volatility around comparator-arm clarity.
The company disclosed a specific FDA meeting type and timing, plus expectations for interim 3-year OS data and downstream decisions (RMAT, Rolling Review, comparator arm). While not an approval, it is a concrete regulatory step tied to efficacy interpretation.
Market effects
Highlights FDA focus on statistical control selection (pooled non-concurrent historical controls vs concurrent natural history) for oncology gene-edited therapies, which can influence expectations for similar programs.
U.K. MHRA also granted a statistical methods Scientific Advice Meeting, reinforcing parallel EU/UK regulatory engagement for the same dataset.
Supports broader investor focus on how regulators handle historical controls and biomarker qualification in rare oncology indications.
Counterpoint
A Type C statistical methods meeting can also surface methodological concerns; until comparator-arm acceptability is confirmed, the path to BLA/Accelerated Approval remains uncertain.
Key entities
- companyOS Therapies, Inc.
Sponsor of OST-HER2 and recipient of the FDA Type C Statistical Methods meeting and MHRA Scientific Advice Meeting.
- productOST-HER2
Gene-edited, Listeria-based immunotherapy whose 2.5-year and interim 3-year overall survival data are under FDA statistical-methods review.
- regulatorFDA (CBER/CDER)
CBER is responsible for gene-edited product approval; CDER biomarker qualification meeting is pending in parallel.
- regulatorMHRA
Granted a U.K. Scientific Advice Meeting to review statistical methods for the conditional marketing authorization application.
